Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) (NEO:MYCO) CEO Joshua Bartch tells Proactive it has partnered with Principal Investigator Dr Matthew Johnson of Johns Hopkins University on a study evaluating the administration of its lead drug candidate MYCO-001, a pure psilocybin from natural fungal sources, with a structured smoking cessation treatment program in nicotine-dependent individuals.
Bartch says Dr Johnson, who has published extensively on the science of psychedelics, has been contracted by Mydecine to complete the phase 2/3 clinical trial of his ongoing research and develop methodologies to better advance future-controlled studies and clinical trials of psychedelics.